



Informazioni personali

Nome / Cognome SEBASTIANO FILETTI

Dipartimento Medicina Interna e Specialità Mediche
Università di Roma- Azienda Policlinico Umberto I- Viale del Policlinico,155 00161 Roma

Settore Scientifico-Disciplinare MED/09 Medicina Interna

Indirizzo Viale del Policlinico, 155 - 00161 Roma

Telefono

Fax

Attuale Posizione **Professore Ordinario** di Medicina Interna presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Roma "Sapienza"

Responsabile U.O.C. di Medicina Interna e Malattie Metaboliche – Azienda Policlinico Umberto I - Roma

Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia "A", Sapienza Università di Roma

Coordinatore della Scuola di Specializzazione in Medicina Interna dell'Università degli Studi di Roma "Sapienza"

Coordinatore Dottorato di Ricerca "Tecnologie biomediche in Medicina Clinica" (cod. 11124)" Università degli Studi di Roma "Sapienza"

Coordinatore Tronco comune Scuole di Specializzazione di Area Medica "Sapienza" Università di Roma
Docente presso le Scuole di Specializzazione dell'Università degli Studi di Roma "Sapienza": Scuola di Specializzazione in Medicina Interna; Scuola di Specializzazione in Endocrinologia e Malattie del Ricambio; Scuola di Specializzazione in Gastroenterologia

Formazione

Professore Ordinario di Medicina Interna, Università di Roma "Sapienza" dal 2001 ad oggi

Professore Ordinario di Medicina Interna, Università di Catanzaro dal 1997 - 2001

Professore Ordinario di Endocrinologia, Università di Catanzaro, 1994-97

Professore Associato di Endocrinologia, Università di Reggio Calabria, Catanzaro 1987-1993

Ricercatore in Patologia Medica, Università di Catania, 1980-1987

Specializzazione in Endocrinologia, Catania, luglio 1975

Laurea in Medicina e Chirurgia, Catania, 30 novembre 1973

Madrelingua Italiano

Other language(s)

Inglese
Francese

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	C1
C1	C1	C1	C1	C1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Premi:

1979 Grant Fullbright-Hays
1979 Premio della Società Italiana di Diabetologia
1984 Premio della Società Italiana di Endocrinologia
1997 Premio della Società Italiana di Endocrinologia

Altre capacità e competenze**Società scientifiche:**

Endocrine Society, American Thyroid Association, American Diabetes Association, Società di Medicina Interna, Società Italiana di Endocrinologia, Società Italiana di Diabetologia, Società Italiana per lo Studio dell'Arteriosclerosi (SISA)

Altre capacità e competenze

Dal 2014 è Associate Editor della rivista "Endocrine", Springer, N.Y.
Dal gennaio 2003 fa parte del consiglio scientifico dell'EFEC (Ecole de Formation Européenne en Cancérologie).
Componente del Comitato Scientifico della Società Italiana di Endocrinologia, delle Giornate Italiane della Tiroide; dell'Editorial Board di "The Journal of Endocrinological Investigation".
Da gennaio 2004 al 2009, membro dell'Editorial Board di "The Journal of Clinical Endocrinology and Metabolism".

Altre capacità e competenze**Esperienze in laboratori esteri:**

1 anno a Bruxelles (Belgio), 1 anno a Londra (Gran Bretagna), 5 anni presso l'Università della California, San Francisco (USA).
In atto collabora con Department of Endocrine Neoplasia & Hormonal Disorders, M.D. Anderson, University of Texas, Houston, USA e con L'Istituto Tumori Gustave-Roussy, Parigi
esperienza di ricerca in metabolismo ed endocrinologia cellulare/molecolare e clinica.

**Inviti a Seminari, Congressi da
altre Istituzioni**

- Chicago, ICE/ENDO Annual Meeting & Expo 20-24 giugno 2014
- Roma, Ospedale San Filippo Neri "Le politiche del Farmaco: ...dieci anni dopo". 12 giugno 2014
- Roma, Università Cattolica del Sacro Cuore, 22-23 novembre 2013

Sperimentazioni Cliniche:

Il Professor Sebastiano Filetti ha maturato esperienza clinica in qualità di responsabile di U.O.C. di Medicina Interna dal 1994 ad oggi. Ha partecipato a numerosi trials clinici, ed è stato responsabile di ricerca di circa 40 studi clinici negli ultimi anni. (Phase II, Phase III)

**Brief Summary of Relevant Clinical Research
Experience:**

06 trials in the cardiovascular field
10 trials in metabolism/dyslipidemia
05 endocrine oncology and thyroid cancer
18 trials in Type II Diabetes
GCP training at investigators meeting for these studies

EXPERIENCE IN SELECTED CLINICAL TRIALS

Novo Nordisk-NN2211-1860	2008	2010	The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes
Bayer-ARRIVE	2008	2014	Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Protocol XL 184-301	2009	2014	Phase 3 XL184 in Metastatic Medullary Thyroid Cancer
Novo Nordisk-NN1250-3582	2008	2010	Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment
Novo Nordisk-12503667	2009	2011	An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine in Type 2 Diabetes
Astrazeneca-DI1690C00004	2008	2010	Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes
Novartis-CLAF237B2224	2008	2010	Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
EISAI 7080-G000-201	2010	8/2015	Phase II Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable
Astrazeneca-D4200C00088	2010	2014	Differentiated Thyroid Cancers Studio di fase 3 randomizzato, multicentrico, sottoposti a trattamento con Vandetanib
Merck-MK0431.102	2009	2010	Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus
NovoNordisk-EX2211-3748	2010	8/2015	Liraglutide Effect on Cardiovascular Events
Lilly -Ebirios H80-IT-B014	2010	2012	Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study
Medtronic-OPT2MISE	2011	2013	OpT2Mise glucose control in type 2 DM with insulin pump therapy
Merck-MK0431.403	2011	2012	Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus
Novartis-CSPP100E2337	2007	2012	Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality
Merck-MK0431.260	2012	2013	To Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus
Novartis-CLAF237A 23156	2012	8/2015	Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Novo Nordisk-1250-3944	2012	2013	The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes
Merck-MK3102-018	2013	8/2015	Study to Assess Cardiovascular Outcomes With MK-3102 in Subjects With Type 2 Diabetes Mellitus
AstraZeneca-D4200C00058	2007	8/2015	An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
EISAI-E7080-G000-303	2011	8/2015	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
AstraZeneca-D4200C00097	2012	8/2015	An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease

Novo Nordisk-NN9535-3624	2013	8/2015	Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes
Novo Nordisk-NN9924-3790	2013	2014	Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide (NNC0113-0217) in subjects with type 2 diabetes
Novo Nordisk-EX1250-4080	2014	8/2015	A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events
AstraZeneca-D1532C00065	2014	8/2015	Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
AstraZeneca-D4203C00011	2014	8/2015	Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
EISAI-Lenvatinib expanded access program	2015	8/2015	An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

1. **“Non toxic goiter and thyroid neoplasia”** pubblicato nel volume **Williams Textbook of Endocrinology** – 13th Edition 2015, Editors: Larsen, Kronenberg, Melmed, Polonsky, Saunders Publisher
2. Sebastiano Filetti, Cosimo Durante, Clark/Duh **Radioactive Iodine Therapy: Mechanisms and Indications** : Endocrine Surgery textbook JP Brothers Medical Publishers, 2015
3. Maria Chiara Zatelli, Efisio Puxeddu, Elisa Menicali, Ettore degli Uberti, and Sebastiano Filetti **Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies** Springer International Publishing Switzerland 2015 C.P. Lombardi, R. Bellantone (eds.), Minimally Invasive Therapies for Endocrine Neck Diseases
4. S. Filetti, R. Michael Tuttle, Steven I. Sherman **Medical Management of differentiated epithelial cell thyroid cancer** pubblicato nel volume “Werner & Ingbar’s the Thyroid, a Fundamental and Clinical Text” Editors: Braverman L, Cooper DS. , 10th Edition. Philadelphia, Lippincott Williams & Wilkins, 2013. Chapter 50E, pag. 725-743.
5. **“Non toxic goiter and thyroid neoplasia”** pubblicato nel volume **Williams Textbook of Endocrinology** – 12th Edition 2011, chapter 14, Editors: Larsen, Kronenberg, Melmed, Polonsky, Saunders Publisher
6. **“Carcinoma midollare della tiroide: genetica e diagnostica molecolare”** pubblicato nel volume **La Tiroide, Fisiopatologia, diagnostica molecolare – clinica e terapia**, 2004, Editor: Andreoli, Il Pensiero Scientifico Publisher
7. **“L’Algoritmo diagnostico”** pubblicato nel volume **Tiroide, diagnostica per immagini e approccio clinico ragionato**, Editors: Lagalla, Attard, Latteri, Midiri, Idelson-Gnocchi Publisher 2004
8. **“Multiple endocrine neoplasia 2”** pubblicato nel volume **Update in Neuroendocrinology**, Editors: Baldelli, Casanueva, Tamburrano, Pubblicazioni Medico Scientifiche Publisher 2004
9. **“Meccanismo di secrezione, dell’azione ormonale e della risposta tissutale”** pubblicato nel volume **Endocrinologia**, 1992 Editors: Pinchera, Fenzi, UTET Publisher

PROCEEDING MEETINGS OF REPORTS:

1. Arturi F, Chiefari E, Scarpelli D, Russo D, **Filetti S**
“Strumenti di diagnosi molecolare in endocrinologia” pubblicato nel volume Aspetti di diagnosi molecolare e terapia genica delle neoplasie endocrine, (Atti del convegno – Padova, 29 ottobre 1999) Editors: Barzon, Bonaguro, Boscaro, Palù 2000 -Time Science Publisher
2. Russo D, Arturi F, Ferretti E, **Filetti S**
“Iodine transport in normal and neoplastic thyroid cells” pubblicato nel volume “Signal transduction and neoplastic transformation in endocrine systems: molecular mechanisms and clinical aspects” (Atti del Convegno presso l’Accademia Nazionale dei Lincei 5-6/04/2002), Bardi Editore Publisher
3. Irace C, Maranghi M, **Filetti S**
“Ipotiroidismo, lipidi e rischio cardiovascolare” pubblicato nel volume Ipotiroidismi: dalla fisiopatologia al trattamento, (Atti del convegno – Vicenza, 27 maggio 2005) Editors: Basso A., Giochetti M.
- 2006
4. Durante C, Romagnoli E, Maranghi M, D’Aloiso L, Minisola S, D’Erasmus E, **Filetti S**
Hyperparathyroidism in multiple endocrine neoplasia type IIA
Clinical Cases in Mineral and Bone Metabolism 2006, 3(2): 162 – 166
5. **Filetti S**, Durante C, Maranghi M
A genetic based disease management in inherited cancer syndromes: the multiple endocrine neoplasia model.
Supportive & Palliative Cancer Care, Suppl. 2006, 2: 13-16

PEER-REVIEWED ARTICLES

H INDEX = 50 (ISI WEB OF SCIENCE) Times cited : 7.737

1. Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, Durante C, Celano M, Russo D, **Filetti S**, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. *Endocrine*. 2015 Apr 12. [Epub ahead of print]
2. De Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, **Filetti S**, Piana S, Frasoldati A, Tallini G, Ciarrocchi A. Tert promoter mutations in thyroid papillary microcarcinomas. *Thyroid*. 2015 Jul 6. [Epub ahead of print]
3. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, **Filetti S**. The natural history of benign thyroid nodules. *JAMA*. 2015 Mar 3;313(9):926-35. doi: 10.1001/jama.2015.0956.
4. Baldan F, Mio C, Allegri L, Puppini C, Russo D, **Filetti S**, Damante G. Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer Derived Cell Line. *Int J Endocrinol*. 2015;2015:978371. doi: 10.1155/2015/978371
5. Lamartina L, Durante C, **Filetti S**, Cooper DS. Low and intermediate Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature. *J Clin Endocrinol Metab*. 2015 Feb 13;jc20143882.
6. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, **Filetti S**. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. *Expert Opin Drug Metab Toxicol*. 2015 Jan;11(1):125-37. doi: 10.1517/17425255.2015.986457.
7. Reznik Y, Huang S; OpT2mise Study Group. Reductions in A1C with pump therapy in type 2 diabetes are independent of C peptide and anti glutamic acid decarboxylase antibody concentrations. *Diabetes Technol Ther*. 2014 Nov;16(11):816-8. doi: 10.1089/dia.2014.0261.
8. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open label controlled trial. *Lancet*. 2014 Oct 4;384(9950):1265-72. doi: 10.1016/S0140-6736(14)61037-0.
9. Micali S, Bulotta S, Puppini C, Territo A, Navarra M, Bianchi G, Damante G, **Filetti S**, Russo D. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. *BMC Cancer*. 2014 Apr 30. doi: 10.1186/1471-2407-14-303.
10. Baldan F, Lavarone E, Di Loreto C, **Filetti S**, Russo D, Damante G, Puppini C. Histone post translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene. *Mol Biol Rep*. 2014 May 21;doi: 10.1007/s11033-014-3397-x
11. Paolino D, Cosco D, Gaspari M, Celano M, Wolfram J, Voce P, Puxeddu E, **Filetti S**, Celia C, Ferrari M, Russo D, Fresta M. Targeting the thyroid gland with thyroid stimulating hormone (TSH) nanoliposomes. *Biomaterials*. 2014 Aug. doi: 10.1016/j.biomaterials.2014.04.088
12. Sponziello M, Durante C, Boichard A, Dima M, Puppini C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, **Filetti S**. Epigenetic related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. *Mol Cell Endocrinol*. 2014 Jul 5. doi: 10.1016/j.mce.2014.04.016.
13. Aronson R, Cohen O, Conget I, Runzis S, Castaneda J, de Portu S, Lee S, Reznik Y; OpT2mise Study Group. OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes research design and methods. *Diabetes Technol Ther*. 2014 Jul. doi: 10.1089/dia.2013.0363.
14. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Totada M, Redler A, Ronga G, **Filetti S**, Monzani F. Clinical aggressiveness and long term outcome in patients with papillary thyroid cancer and circulating anti thyroglobulin autoantibodies. *Thyroid*. 2014 Jul;24. doi: 10.1089/thy.2013.0698.
15. Puppini C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, **Filetti S**, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov; [Epub 2014 Feb 26. doi: 10.1007/s12020-014-0204-3]
16. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, **Filetti S**, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E. Indoleamine 2,3 Dioxygenase 1 (IDO1) Is Up Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. *J Clin Endocrinol Metab*. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013.3351.
17. Puxeddu E, **Filetti S**. BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? *Endocrine*. 2014 Apr;45(3):341-3. doi: 10.1007/s12020-013-0139-0.
18. D'Agostino M, Sponziello M, Puppini C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, **Filetti S**, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. *J Mol Endocrinol*. 2014 Jan 30;52(2):121-31. doi: 10.1530/JME-13-0160.
19. Maggisano V, Puppini C, Celano M, D'Agostino M, Sponziello M, Micali S, Navarra M, Damante G, **Filetti S**, & Russo D. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. *Endocrine*. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4.
20. Grande E, Kreissl MC, **Filetti S**, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J. Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies. *Adv Ther*. 2013 Nov 19. doi: 10.1007/s12325-013-0069-5
21. Essig GF, Porter K, Schneider D, Debora A, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas L, Sharma N, Costante G, **Filetti S**, Sippel RS, Biondi B,

- Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Fine Needle Aspiration and Medullary Thyroid Carcinoma: The Risk of Inadequate Preoperative Evaluation and Initial Surgery when Relying Upon FNAB Cytology Alone. *Endocr Pract.* 2013 Jun 11;1: 27. doi: 10.4158/EP13143.OR.
22. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppini C, Russo MA, Bruno R, **Filetti S**, Durante C, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. *Endocrinology.* 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013.1028.
 23. Bulotta S, Corradino R, Celano M, Maiuolo J, D'Agostino M, Oliverio M, Procopio A, **Filetti S**, Russo D. Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells. *J Mol Endocrinol.* 2013 Jun 29;51(1):181-9. doi: 10.1530/JME.12.0241.
 24. Aghini Lombardi F, Vitti P, Antonangeli L, Fiore E, Piaggi P, Pallara A, Consiglio E, Pinchera A; Southern Italy Study Group for Iodine Deficiency Disorders. The size of the community rather than its geographical location better defines the risk of iodine deficiency: results of an extensive survey in Southern Italy. *J Endocrinol Invest.* 2013 May;36(5):282-6.
 25. Durante C, Paciaroni A, Plasmati K, Trulli F, **Filetti S** Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. *Endocrine.* 2013 Oct;44(2):334-42. doi: 10.1007/s12020-013-9943-9.
 26. Durante C, Costante G, **Filetti S**. Differentiated thyroid carcinoma: defining new paradigms for the post operative management. *Endocr Relat Cancer.* 2013 Jun 24;20(4):R141-54. doi: 10.1530/ERC-13-0066.
 27. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, **Filetti S**; Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. *J Clin Endocrinol Metab.* 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012.3401.
 28. Russo D, Durante C, Bulotta S, Puppini C, Puxeddu E, **Filetti S**, Damante G. Targeting histone deacetylase in thyroid cancer. *Expert Opin Ther Targets.* 2013 Feb;17(2):179-93. doi: 10.1517/14728222.2013.740013.
 29. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA; **ALTITUDE Investigators** Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med.* 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799.
 30. Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, **Filetti S**, Russo D. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. *J Endocrinol.* 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE.12.0495.
 31. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivelles AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Addition of either pioglitazone or a sulphonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. *Nutr Metab Cardiovasc Dis.* 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003.
 32. D'Elia AV, Grimaldi F, Pizzolitto S, De Maglio G, Bregant E, Passon N, Franzoni A, Verrienti A, Tamburrano G, Durante C, **Filetti S**, Fogolari F, Russo D, Damante G. A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. *Clin Endocrinol (Oxf).* 2012 Sep 5. doi: 10.1111/cen.12032.
 33. Lavarone E, Puppini C, Passon N, **Filetti S**, Russo D, Damante G. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. *Mol Cell Endocrinol.* 2012 Sep 5. pii: S0303-7207(12)00414-5. doi: 10.1016/j.mce.2012.08.019.
 34. Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M; for the 1860 LIRA DPP 4 Study Group. Efficacy and Safety of Switching From the DPP 4 Inhibitor Sitagliptin to the Human GLP 1 Analog Liraglutide After 52 Weeks in Metformin Treated Patients With Type 2 Diabetes: A randomized, open label trial. *Diabetes Care.* 2012 Oct;35(10):1986-93.]
 35. Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D. Increased expression of pro angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine.* 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3.
 36. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S. Long Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? *J Clin Endocrinol Metab.* 2012 Aug;97(8):2748-2753.
 37. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250 3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra longacting basal insulin, versus insulin glargine in basal bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal Bolus Type 2): a phase 3, randomised, open label, treat to target non inferiority trial. *Lancet.* 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.
 38. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, Durante C, Russo D, Filetti S, Damante G. Cyclic AMP response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells. *Thyroid.* 2012 May;22(5):487-93. doi: 10.1089/thy.2011.0360.
 39. Maranghi M, Prudente S, D'Erasmo L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA, Morano S, Filetti S, Trischitta V. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non diabetic individuals. *Nutr Metab Cardiovasc Dis.* 2013 Jun;23(6):505-10. doi: 10.1016/j.numecd.2011.11.003.]
 40. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman J, Fenton M, D'Agostino M, Durante C, Russo D, **Filetti S**, Damante G. CREM inhibits promoter activity of NIS gene in thyroid cancer cells. *Thyroid.* 2012 Feb 28.

41. D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. *Thyroid*. 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060.
42. Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, Durante C, **Filetti S**. TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. *Endocrine*. 2011 Dec;40(3):492-4. doi: 10.1007/s12020-011-9525-7
43. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, **Filetti S**, Russo D, Durante C. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep*. 2011 Nov;26(5):1075-80. doi: 10.3892/or.2011.1422.
44. Durante C, **Filetti S**. Management of Papillary Thyroid Cancer Patients in Absence of Postoperative Radioiodine Remnant Ablation: tailoring Follow Up by Neck Sonography. *J Clin Endocrinol Metab*. 2011 Oct;96(10):3059-61. doi: 10.1210/jc.2011.1379
45. Mastroianno S, Torlontano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, Durante C, **Filetti S**. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. *Endocrine*. 2011 Dec;40(3):481-5. doi: 10.1007/s12020-011-9501-2
46. Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, **Filetti S**. BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol*. 2011 Sep;165(3):455-63. doi: 10.1530/EJE-11-0283
47. Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggisano V, Paoli D, Verrienti A, Costante G, Lenzi A, **Filetti S**. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. *Endocrine*. 2011 Aug;40(1):35-40. doi: 10.1007/s12020-011-9469-y
48. Pianta A, Puppini C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, **Filetti S**, Russo D, Damante G. Nucleophosmin is overexpressed in thyroid tumors. *Biochem Biophys Res Commun*. 2010 Jul 2;397(3):499-504. doi: 10.1016/j.bbrc.2010.05.142
49. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, **Filetti S**, Garber A, Thomsen AB, Hartvig H, Davies M; for the 1860 LIRA DPP 4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel group, open label trial. *Int J Clin Pract*. 2011 Mar 1. doi: 10.1111/j.1742-1241.2011.02656.x.
50. Russo D, Damante G, Puxeddu E, Durante C, **Filetti S**. Epigenetics of thyroid cancer and novel therapeutic targets. *J Mol Endocrinol*. 2011 Apr 28;46(3):R73-81. doi: 10.1530/JME-10-0150
51. Durante C, Russo D, Verrienti A, **Filetti S**. XL184 (cabozantinib) for medullary thyroid carcinoma. *Expert Opin Investig Drugs*. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163
52. Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, **Filetti S**, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol*. 2012 Jun;49(3):193-7. doi: 10.1007/s00592-011-0261-5
53. Costante G, **Filetti S**. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? *Oncologist*. 2011;16(1):49-52. doi: 10.1634/theoncologist.2010.0344
54. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, **Filetti S**. Identification and optimal postsurgical follow up of patients with very low risk papillary thyroid microcarcinomas. *J Clin Endocrinol Metab*. 2010 Nov;95(11):4882-8. doi: 10.1210/jc.2010.0762
55. Zinamosca L, Petramala L, Cotesta D, Marinelli C, Sciomer S, Cavallaro G, Ciardi A, Massa R, De Toma G, **Filetti S**, Letizia C. Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. *Endocrine*. 2010 Dec;38(3):313-9. doi: 10.1007/s12020-010-9394-5
56. Sponziello M, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, **Filetti S**, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res*. 2011 Jan;43(1):22-5. doi: 10.1055/s-0030-1265226
57. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, **Filetti S**, Thomsen AB, Søndergaard RE, Davies M; 1860 LIRA DPP 4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26 week, randomised, parallel group, open label trial. *Lancet*. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.
58. Paolino D, Cosco D, Racanicchi L, Trapasso E, Celia C, Iannone M, Puxeddu E, Costante G, **Filetti S**, Russo D, Fresta M. Gemcitabine loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. *J Control Release*. 2010 Jun 1;144(2):144-50. doi: 10.1016/j.jconrel.2010.02.021.
59. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S. Atorvastatin downregulates monocyte CD36 expression, nuclear NF-kappaB and TNF-alpha levels in type 2 diabetes. *J Atheroscler Thromb*. 2010 Jun 30;17(6):539-45.
60. Castellone MD, Verrienti A, Rao DM, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, **Filetti S**. A novel de novo germ line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: Functional characterization. *Clin Endocrinol (Oxf)*. 2010 Oct;73(4):529-34. doi: 10.1111/j.1365-2265.2009.03757.
61. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, **Filetti S**, Bianchi Russo D. Expression of the sodium/iodide symporter in human prostate adenocarcinoma. *Urology*. 2010 Apr;75(4):773-8. doi: 10.1016/j.urology.2009.10.011.
62. Suh I, **Filetti S**, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark I. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNF

array based linkage analysis of 38 families. *Surgery*. 2009 Dec;146(6):1073-80. doi: 10.1016/j.surg.2009.09.012

63. Cotesta D, Petramala L, Serra V, Pergolini M, Crescenzi E, Zinnamosca L, De Toma G, Ciardi A, Cart Massa R, **Filetti S**, Letizia C. Clinical experience with pheochromocytoma in a single centre over 16 y. *High Blood Press Cardiovasc Prev*. 2009 Dec;16(4):183-93. doi: 10.2165/11530430
64. Puxeddu E, **Filetti S**. The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus to evidence based practice. *Thyroid*. 2009;19(11):1145-7. doi: 10.1089/thy.2009.1601
65. Maranghi M, Pugliese F, Cianci R, Colotto M, Durante C, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, **Filetti S**. Atherosclerosis renal artery stenosis and in stent restenosis in diabetic patient: targeting on Diabetic Dyslipidemia is a key intervention. *J Endocrinol Invest*. 2009 Oct 15; doi: 10.3275/6567.
66. Sponziello M, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, **Filetti S**, Russo D Regulation of Sodium/Iodide Symporter and Lactoperoxidase Expression in four Human Breast Cancer Cell Lines. *J Endocrinol Invest*. 2009 Sep 30. doi: 10.3275/6522
67. Corleto VD, Cotesta D, Petramala L, Panzuto F, Pagnini C, Masoni L, Verrienti A, Delle Fave G, **Filetti S**, Letizia C. Late recurrence after surgical resection of a pancreatic tumor in von Hippel Lindau disease. *JOP*. 2009;10(5):562-5.
68. Marques LH, Ferraz Filho JR, Lins Filho ML, Maciel MG, Yoshitake R, **Filetti S**. Interictal SPECT in the presurgical evaluation in epileptic patients with normal MRI or bilateral mesial temporal sclerosis. *Arq Neuropsiquiatr*. 2009 Sep;67(3A):639-42.
69. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V, **Filetti S**. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. *Diabetes Care*. 2009;32(8):1550-2. doi: 10.2337/dc09.0256
70. Costante G, **Filetti S**. Diagnosis: Thyroglobulin in fine needle aspirates a clue to metastasis? *Nat Rev Endocrinol*. 2009; 5(5):249-50. doi: 10.1038/nrendo.2009.55
71. Gatti A, Baroni MG, Romeo S, Mandosi E, Fallarino M, Bezzi M, Paciucci L, **Filetti S**, Morano S. A case of severe occult ectopic adrenocorticotropin syndrome treated with retrograde venous adrenal ablation using ethanol. *J Endocrinol Invest*. 2008 Dec;31(12):1135-6.
72. Bruno R, Giannasio P, Chiarella R, Capula C, Russo D, **Filetti S**, Costante G. Identification of a neck lump as a lymph node metastasis from an occult contralateral papillary microcarcinoma of the thyroid: key role of thyroglobulin assay in the fine needle aspirate. *Thyroid*. 2009;19(5):531-3. doi: 10.1089/thy.2009.0049
73. Mannelli M, Castellano M, Schiavi F, **Filetti S**, Giacchè M, Mori L, Pignataro V, Bernini G, Giachè V, Bacca A, Biondi B, Corona G, Di Trapani G, Grossrubatscher E, Reimondo G, Arnaldi G, Giacchetti G, Veglio F, Loli P, Colao A, Ambrosio MR, Terzolo M, Letizia C, Ercolino T, Opocher G; Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. *J Clin Endocrinol Metab*. 2009;94(5):1541-7. doi: 10.1210/jc.2008.2419
74. Franzoni A, Dima M, D'Agostino M, Puppini C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, **Filetti S**, Russo D, Damante G. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. *Thyroid*. 2009;19(3):247-55. doi: 10.1089/thy.2008.0235
75. Venditti M, Falcone M, Corrao S, Licata G, Serra P; **Study Group of the Italian Society of Internal Medicine** Outcomes of patients hospitalized with community acquired, health care associated, and hospital acquired pneumonia. *Ann Intern Med*. 2009 Jan 6;150(1):19-26.
76. Costante G, Durante C, Francis Z, Schlumberger M, **Filetti S**. Determination of calcitonin levels in C cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab*. 2009;5(1):35-44. doi: 10.1038/ncpendmet1023.
77. Petramala L, Cotesta D, **Filetti S**, Letizia C. Pigmented 'black' cardiac paraganglioma in a patient with a novel germ line mutation. *Eur J Cardiothorac Surg*. 2008;35:189. doi: 10.1016/j.ejcts.2008.10.007
78. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfinto N, Dicembrino F, Varraso A, Meringolo D, **Filetti S**, Trischitta V, Tortolano M. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. *Thyroid*. 2008;18(10):1049-53. doi: 10.1089/thy.2008.0160
79. Capezzone M, Cantara S, Marchisotta S, **Filetti S**, De Santi MM, Rossi B, Ronga G, Durante C, Pacini F. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. *J Clin Endocrinol Metab*. 2008;93(10):3950-7. doi: 10.1210/jc.2008.0372
80. Ferretti E, Tosi E, Po A, Scipioni A, Morisi R, Espinola MS, Russo D, Durante C, Schlumberger M, Screpanti I, **Filetti S**, Gulino A. Notch signaling is involved in expression of thyrocyte differentiation markers and is down regulated in thyroid tumors. *J Clin Endocrinol Metab*. 2008;93(10):4080-7. doi: 10.1210/jc.2008.0528
81. Durante C, Cava F, Paciaroni A, **Filetti S**. Benign thyroid nodules: diagnostic and therapeutic approach. *Recenti Prog Med*. 2008;99(5):263-70
82. Pippi F, Bracciale L, Stolzoli L, Giaccherini R, Montomoli E, Gentile C, **Filetti S**, De Luca A, Cellesi C. Serological response to hepatitis B virus vaccine in HIV infected children in Tanzania. *HIV Med*. 2008 Aug;9(7):519-25. Epub 2008 Jun 28. doi: 10.1111/j.1468.1293.2008.00598
83. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. *Endocr Relat Cancer*. 2008;15(2):499-510. doi: 10.1677/ERC.07.0243
84. Petramala L, Cavallaro G, Polistena A, Cotesta D, Verrienti A, Ciardi A, Lucia P, **Filetti S**, D'Erasmo E, De Toma G, Letizia C. Multiple catecholamine secreting paragangliomas: diagnosis after hemorrhagic stroke in a young woman. *Endocr Pract*. 2008;14(3):340-6.
85. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators Efficacy and tolerability of rosuvastatin and atorvastatin when force titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. *Cardiology*. 2008;111(4):219-28. doi: 10.1159/000127442
86. Puppini C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G. High

- periostin expression correlates with aggressiveness in papillary thyroid carcinomas. *J Endocrinol*. 2008;197(2):401 8. doi: 10.1677/JOE 07 0618
87. Xu J, **Filetti S**, Hershman JM. Expression of hepatocyte nuclear factor 1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors. *Thyroid*. 2008;18(5):533 9. doi: 10.1089/thy.2007.0312
 88. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. *Trends Endocrinol Metab*. 2008;19(4):138 45. doi: 10.1016/j.tem.2007.12.003
 89. Vendrame F, Verrienti A, Parlapiano C, Filetti S, Dotta F, Morano S. Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. *Ann Clin Biochem*. 2008;45(Pt 2):218 20. doi: 10.1258/acb.2007.007117
 90. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, **Filetti S**, Botta M, Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo pyrimidine derivatives. *J Endocrinol Invest*. 2007;30(10):RC31 4.
 91. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, **Filetti S**, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. *J Clin Endocrinol Metab*. 2008;93(3):910 3.
 92. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, Meringolo D, Arturi F, Durante C, Amorosi A, Foschini MP, Nardi F, Russo D, **Filetti S**. hNIS protein in thyroid: the iodine supply influences its expression and localization. *Thyroid*. 2007;17(7):613 8.
 93. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, **Filetti S**, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab*. 2007 ;92(7):2840 3.
 94. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, Durante C, Maranghi M, **Filetti S**, Russo D. Radioiodine uptake in non lactating mammary glands: evidence for a causative role of hyperprolactinemia. *Thyroid*. 2007;17(4):363 6.
 95. Faggiano A, Caillou B, Lacroix L, Talbot M, **Filetti S**, Bidart JM, Schlumberger M. Functional characterization of human thyroid tissue with immunohistochemistry. *Thyroid*. 2007;17(3):203 11.
 96. Schlumberger M, Lacroix L, Russo D, **Filetti S**, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow up and treatment of patients. *Nat Clin Pract Endocrinol Metab*. 2007;3(3):260 9.
 97. Maranghi M, Coletta P, Durante C, Pergolini D, **Filetti S**. Cardiovascular disease and metabolic syndrome Recenti Prog Med. 2006;97(12):719 26.
 98. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, **Filetti S**. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab*. 2007 ;92(2):450 5.
 99. **Filetti S**, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. *Nat Clin Pract Endocrinol Metab*. 2006;2(7):384 94.
 100. Biondi B, **Filetti S**, Schlumberger M. Thyroid hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab*. 2005;1(1):32 40.
 101. Pines A, Bivi N, Vascotto C, Romanello M, D'Ambrosio C, Scaloni A, Damante G, Morisi R, **Filetti S**, Ferretti E, Quadrioglio F, Tell G. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref 1 in thyroid cancer cells: a novel tumorigenic pathway. *J Cell Physiol*. 2006;209(1):44 55.
 102. Caliumi C, Cotesta D, Petramala L, Lorio M, Salvati M, **Filetti S**, De Toma G, D'Erasmo E, Letizia C. An unusual association of cerebral meningioma, parathyroid adenoma and thyroid papillary carcinoma. *Tumori*. 2006;92(2):178 80.
 103. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, **Filetti S**, Schlumberger M, Bidart JM. HEX, PAX 8 and TTF 1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. *Clin Endocrinol (Oxf)*. 2006;64(4):398 404.
 104. D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, **Filetti S**. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low penetrant nonaggressive familial medullary thyroid carcinoma. *J Clin Endocrinol Metab*. 2006;91(3):754 9
 105. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, **Filetti S**, Trischitta V. Comparative evaluation of recombinant human thyrotropin stimulated thyroglobulin levels, 131I whole body scintigraphy, and neck ultrasonography in the follow up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab*. 2006;91(1):60 3.
 106. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, **Filetti S**, Russo D. Modulation of thyroid specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. *J Clin Endocrinol Metab*. 2005;90(10):5692 7.
 107. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, **Filetti S**, Russo D. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. *BMC Cancer*. 2005 19;5:80.
 108. Ferretti E, Arturi F, Mattei T, Scipioni A, Tell G, Tosi E, Presta I, Morisi R, Lacroix L, Gulino A, Russo D, Damante G, **Filetti S**. Expression, regulation, and function of paired box gene 8 in the human placenta and placental cancer cell lines. *Endocrinology*. 2005;146(9):4009 15.
 109. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, **Filetti S**, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid specific transcription factors. *Endocrinology*. 2005 ;146(9):3967 74.
 110. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, **Filetti S**, Scaloni A, Damante G, Tell G. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn SOD in poorly differentiated thyroid cancer cells. *J Endocrinol Invest*. 2005;28(2):137 44.
 111. Biondi B, Palmieri EA, Klain M, Schlumberger M, **Filetti S**, Lombardi G. Subclinical hyperthyroidism:

- clinical features and treatment options. *Eur J Endocrinol*. 2005 ;152(1):1 9.
112. Scarpelli D, D'Aloiso L, Arturi F, Scillitani A, Presta I, Bisceglia M, Cristofaro C, Russo D, **Filetti S**. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. *J Endocrinol Invest*. 2004;27(11):1015 21.
 113. Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, **Filetti S**, Schlumberger M. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. *J Endocrinol Invest*. 2004;27(11):1010 4.
 114. Arturi F, Ferretti E, Presta I, Mattei T, Scipioni A, Scarpelli D, Bruno R, Lacroix L, Tosi E, Gulino A, Russo D, **Filetti S**. Regulation of iodide uptake and sodium/iodide symporter expression in the mcf 7 human breast cancer cell line. *J Clin Endocrinol Metab*. 2005;90(4):2321 6.
 115. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroli D, **Filetti S**, Fresta M, Russo D. Cytotoxic effects of gemcitabine loaded liposomes in human anaplastic thyroid carcinoma cells. *BMC Cancer*. 2004;4:63.
 116. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R, Arturi F, **Filetti S**. Follow up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. *J Clin Endocrinol Metab*. 2004;89(7):3402 7.
 117. Tell G, Pines A, Arturi F, Cesaratto L, Adamson E, Puppini C, Presta I, Russo D, **Filetti S**, Damante G. Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. *Endocrinology*. 2004;145(10):4660 6.
 118. Romeo S, Menzaghi C, Bruno R, Sentinelli F, Fallarino M, Fioretti F, **Filetti S**, Balsamo A, Di Mario U, Baroni MG. Search for genetic variants in the retinoid X receptor gamma gene by polymerase chain reaction single strand conformation polymorphism in patients with resistance to thyroid hormone without mutations in thyroid hormone receptor beta gene. *Thyroid*. 2004;14(5):355 8.
 119. Torrente I, Arturi F, D'Aloiso L, Colosimo A, De Luca A, Ferretti E, Russo D, Chieffari E, Scarpelli D, Bisceglia M, Dallapiccola B, **Filetti S**. Evaluation of a DHPLC based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma. *J Endocrinol Invest*. 2004;27(2):111 6.
 120. Corsetti F, Chianelli M, Cornelissen B, Van de Wiele C, D'Alessandria C, Slegers G, Mather SJ, Di Mario U, **Filetti S**, Scopinaro F, Signore A. Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. *Cancer Biother Radiopharm*. 2004;19(1):57 63.
 121. Puppini C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, **Filetti S**, Damante G. Functional interaction among thyroid specific transcription factors: Pax8 regulates the activity of Hex promoter. *Mol Cell Endocrinol*. 2004;214(1 2):117 25.
 122. Costante G, Crocetti U, Schifino E, Ludovico O, Capula C, Nicotera M, Arturi F, **Filetti S**. Slow growth of benign thyroid nodules after menopause: no need for long term thyroxine suppressive therapy in post menopausal women. *J Endocrinol Invest*. 2004;27(1):31 6.
 123. Mannucci E, Ricca V, **Filetti S**, Boldrini M, Rotella CM. Eating behavior and thyroid disease in female obese patients. *Eat Behav*. 2003 Aug;4(2):173 9.
 124. Puppini C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G, Damante G, **Filetti S**. Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor 1. *Endocrinology*. 2004;145(3):1290 3.
 125. Arturi F, Scarpelli D, Coco A, Sacco R, Bruno R, **Filetti S**, Russo D. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. *Thyroid*. 2003;13(4):341 3.
 126. Celano M, Arturi F, Presta I, Bruno R, Scarpelli D, Calvagno MG, Cristofaro C, Bulotta S, Giannasio P, Sacco R, **Filetti S**, Russo D. Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. *Mol Cell Endocrinol*. 2003;203(1 2):129 35.
 127. Puppini C, D'Elia AV, Pellizzari L, Russo D, Arturi F, Presta I, **Filetti S**, Bogue CW, Denson LA, Damante G. Thyroid specific transcription factors control Hex promoter activity. *Nucleic Acids Res*. 2003;31(7):1845 52.
 128. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, **Filetti S**, Schlumberger M, Trischitta V. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow up of low risk patients with differentiated thyroid cancer. *Eur J Endocrinol*. 2003;148(1):19 24.
 129. Chieffari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, **Filetti S**. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? *BMC Cancer*. 2002 Dec 10;2:35.
 130. Arturi F, Presta I, Scarpelli D, Bidart JM, Schlumberger M, **Filetti S**, Russo D. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL 5 cells: effects on sodium/iodide symporter gene and protein expression. *Eur J Endocrinol*. 2002 Nov;147(5):655 61.
 131. Russo D, Celano M, Bulotta S, Bruno R, Arturi F, Giannasio P, **Filetti S**, Damante G, Tell G. APE/Ref 1 is increased in nuclear fractions of human thyroid hyperfunctioning nodules. *Mol Cell Endocrinol*. 2002 Aug 30;194(1 2):71 6.
 132. Arturi F, Chieffari E, Tumino S, Russo D, Squatrito S, Chazenbalk G, Persani L, Rapoport B, **Filetti S**. Similarities and differences in the phenotype of members of an Italian family with hereditary non autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation. *J Endocrinol Invest*. 2002 Sep;25(8):696 701.
 133. Giardina E, Capon F, D'Apice MR, Amati F, Arturi F, **Filetti S**, Bonifazi E, Pucci S, Conte C, Novelli G. Mutational analysis of Peroxiredoxin IV: exclusion of a positional candidate for multinodular goitre. *BMC Med Genet*. 2002 Jul 23;3:5.
 134. Arturi F, Lacroix L, Presta I, Scarpelli D, Caillou B, Schlumberger M, Russo D, Bidart JM, **Filetti S**. Regulation by human chorionic gonadotropin of sodium/iodide symporter gene expression in the JAr human choriocarcinoma cell line. *Endocrinology*. 2002 Jun;143(6):2216 20.
 135. Costante G, Grasso L, Schifino E, Marasco MF, Crocetti U, Capula C, Chiarella R, Ludovico O, Nocera M, Parlato G, **Filetti S**. Iodine deficiency in Calabria: characterization of endemic goiter and analysis of different indicators of iodine status region wide. *J Endocrinol Invest*. 2002 Mar;25(3):201 7.
 136. Lombardo F, Baudin E, Chieffari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida

- D, Bidart JM, Schlumberger M, **Filetti S**. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. *J Clin Endocrinol Metab*. 2002 Apr;87(4):1674-80.
137. Belfiore A, Russo D, Vigneri R, **Filetti S**. Graves' disease, thyroid nodules and thyroid cancer. *Clin Endocrinol (Oxf)*. 2001 Dec;55(6):711-8.
 138. D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manfioletti G, Gattei V, Mack DL, Cataldi P, **Filetti S**, Di Loreto C, Damante G. Expression and localization of the homeodomain containing protein HEX in human thyroid tumors. *J Clin Endocrinol Metab*. 2002 Mar;87(3):1376-83.
 139. Biondi B, Palmieri EA, **Filetti S**, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. *Lancet*. 2002 Mar 2;359(9308):799-800.
 140. Boland A, Magnon C, **Filetti S**, Bidart JM, Schlumberger M, Yeh P, Perricaudet M. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector mediated gene transfers. *Thyroid*. 2002 Jan;12(1):19-26.
 141. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C, **Filetti S**, Bidart JM, Schlumberger M. Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. *Thyroid*. 2001 Nov;11(11):1017-23.
 142. Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, Bidart JM, Schlumberger M, **Filetti S**. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. *Eur J Endocrinol*. 2001 Nov;145(5):591-7.
 143. Mian C, Lacroix L, Bidart JM, Caillou B, **Filetti S**, Schlumberger M. Sodium/iodide symporter in thyroid cancer. *Exp Clin Endocrinol Diabetes*. 2001;109(1):47-51.
 144. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, **Filetti S**. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. *Eur J Endocrinol*. 2001;145(2):129-35.
 145. Russo D, Arturi F, Bulotta S, Pellizzari L, **Filetti S**, Manzini G, Damante G, Tell G. Apel/Ref 1 expression and cellular localization in human thyroid carcinoma cell lines. *J Endocrinol Invest*. 2001;24(3):RC10-2.
 146. Chiefari E, Chiarella R, Crocetti U, Tardio B, Arturi F, Russo D, Trischitta V, **Filetti S**, Zingrillo M. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. *Horm Metab Res*. 2001; 33(1):52-6.
 147. Lombardo F, **Filetti S**, Crocetti U, Schlumberger M. Medullary thyroid carcinoma and lack of renal agenesis. *Thyroid* 2001;11(1):93.
 148. Russo D, Manole D, Arturi F, Suarez HG, Schlumberger M, **Filetti S**, Derwahl M. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. *Thyroid*. 2001;11(1):37-9.
 149. Lacroix L, Mian C, Caillou B, Talbot M, **Filetti S**, Schlumberger M, Bidart JM. Na⁺/I⁻ symporter and Pendred syndrome gene and protein expressions in human extra thyroidal tissues. *Eur J Endocrinol*. 2001;144(3):297-302.
 150. Orlandi F, Chiefari E, Caraci P, Mussa A, Gonzatto I, De Giuli P, Giuffrida D, Angeli A, **Filetti S**. RET proto oncogene mutation in a mixed medullary follicular thyroid carcinoma. *J Endocrinol Invest*. 2001;24(1):51-5.
 151. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, **Filetti S**, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle aged patients. *J Clin Endocrinol Metab*. 2000;85(12):4701-5.
 152. Camacho P, Gordon D, Chiefari E, Yong S, DeJong S, Pitale S, Russo D, **Filetti S**. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. *Thyroid*. 2000;10(11):1009-12.
 153. Bidart JM, Lacroix L, Evain Brion D, Caillou B, Lazar V, Frydman R, Bellet D, **Filetti S**, Schlumberger M. Expression of Na⁺/I⁻ symporter and Pendred syndrome genes in trophoblast cells. *J Clin Endocrinol Metab*. 2000;85(11):4367-72.
 154. Russo D, Betterle C, Arturi F, Chiefari E, Girelli ME, **Filetti S**. A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. *J Clin Endocrinol Metab*. 2000;85(11):4238-42.
 155. Arturi F, Russo D, Giuffrida D, Schlumberger M, **Filetti S**. Sodium iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. *Eur J Endocrinol*. 2000;143(5):623-7.
 156. Du Villard JA, Wicker R, Crespo P, Russo D, **Filetti S**, Gutkind JS, Sarasin A, Suárez HG. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. *Oncogene*. 2000;19(42):4896-905.
 157. Capon F, Tacconelli A, Giardina E, Sciacchitano S, Bruno R, Tassi V, Trischitta V, **Filetti S**, Dallapiccola B, Novelli G. Mapping a dominant form of multinodular goiter to chromosome Xp22. *Am J Hum Genet*. 2000;67(4):1004-7.
 158. Persani L, Lania A, Alberti L, Romoli R, Mantovani G, **Filetti S**, Spada A, Conti M. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. *J Clin Endocrinol Metab*. 2000;85(8):2872-8.
 159. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, **Filetti S**, Schlumberger M, Perricaudet M. Adenovirus mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. *Cancer Res*. 2000;60(13):3484-92.
 160. Bidart JM, Mian C, Lazar V, Russo D, **Filetti S**, Caillou B, Schlumberger M. Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. *J Clin Endocrinol Metab*. 2000;85(5):2028-33.
 161. Brunetti A, Chiefari E, **Filetti S**, Russo D. The 3',5' cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. *Endocrinology*. 2000;141(2):722-30.
 162. **Filetti S**, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. *Eur J Endocrinol*. 1999;141(5):443-57.
 163. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, **Filetti S**, Schlumberger M. Expression of the Na⁺/I⁻ symporter gene in human thyroid tumors: a comparison study with other thyroid specific genes. *J Clin Endocrinol Metab*. 1999;84(9):3228-34.
 164. Russo D, Arturi F, Pontecorvi A, **Filetti S**. Genetic Analysis in Fine needle Aspiration of the Thyroid:

- A New Tool for the Clinic. *Trends Endocrinol Metab.* 1999;10(7):280-285.
165. Russo D, Arturi F, Chieffari E, **Filetti S**. Thyrotropin receptor: a role for thyroid tumorigenesis? *Forum (Genova)*. 1999;9(2):166-75.
 166. Trapasso F, Iuliano R, Chieffari E, Arturi F, Stella A, **Filetti S**, Fusco A, Russo D. Iodide symporter gene expression in normal and transformed rat thyroid cells. *Eur J Endocrinol.* 1999;140(5):447-51.
 167. Russo D, Wong MG, Costante G, Chieffari E, Treseler PA, Arturi F, **Filetti S**, Clark OH. A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. *Thyroid.* 1999; 9(1):13-7.
 168. Frittitta L, Sciacca L, Catalfamo R, Ippolito A, Gangemi P, Pezzino V, **Filetti S**, Vigneri R. Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis? *Cancer.* 1999;85(2):492-8.
 169. Caillou B, Troalen F, Baudin E, Talbot M, **Filetti S**, Schlumberger M, Bidart JM. Na⁺/I⁻ symporter distribution in human thyroid tissues: an immunohistochemical study. *J Clin Endocrinol Metab.* 1998;83(11):4102-6.
 170. Arturi F, Capula C, Chieffari E, **Filetti S**, Russo D. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. *Exp Clin Endocrinol Diabetes.* 1998;106(3):234-6.
 171. Chieffari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, **Filetti S**. Analysis of RET proto oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. *J Endocrinol Invest.* 1998;21(6):358-64.
 172. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chieffari E, Suarez HG, **Filetti S**. Iodide symporter gene expression in human thyroid tumors. *J Clin Endocrinol Metab.* 1998;83(7):2493-6.
 173. Russo D, Arturi F, Chieffari E, Meringolo D, Bianchi D, Bellanova B, **Filetti S**. A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto oncogene somatic mutation in fine needle aspirate specimens. *J Clin Endocrinol Metab.* 1997;82(10):3378-82.
 174. Costante G, Grasso L, Ludovico O, Marasco MF, Nocera M, Schifano E, Rivalta L, Capula C, Chiarella R, **Filetti S**, Parlato G. The statistical analysis of neonatal TSH results from congenital hypothyroidism screening programs provides a useful tool for the characterization of moderate iodine deficiency regions. *J Endocrinol Invest.* 1997;20(5):251-6.
 175. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R, **Filetti S**. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. *J Clin Endocrinol Metab.* 1997;82(5):1638-41.
 176. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, **Filetti S**, Belfiore A. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. *J Clin Endocrinol Metab.* 1997;82(3):735-8.
 177. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, **Filetti S**, Andreoli M, Sacchi A, Pontecorvi A. p53 re expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. *Oncogene.* 1997;14(6):729-40.
 178. Russo D, Arturi F, Chieffari E, **Filetti S**. Molecular insights into TSH receptor abnormality and thyroid disease. *J Endocrinol Invest.* 1997;20(1):36-47.
 179. Scrofani A, Cioni M, **Filetti S**, Lanaia F, Pennisi G, Bella R, Grasso A. Changes in sleep spindle activity of subject with chronic somatosensitive and sensorial deficits. Preliminary results. *Ital J Neurol Sci.* 1996 Dec;17(6):423-8.
 180. Kakinuma A, Chazenbalk G, **Filetti S**, McLachlan SM, Rapoport B. Both the 5' and 3' noncoding regions of the thyrotropin receptor messenger ribonucleic acid influence the level of receptor protein expression in transfected mammalian cells. *Endocrinology.* 1996;137(7):2664-9.
 181. Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, **Filetti S**. Constitutive activation of the Gs alpha protein adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. *J Clin Endocrinol Metab.* 1996;81(5):1898-904.
 182. Russo D, Arturi F, Suarez HG, Schlumberger M, Du Villard JA, Crocetti U, **Filetti S**. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. *J Clin Endocrinol Metab.* 1996;81(4):1548-51.
 183. Bourdoux PP, Ermans AM, Mukalay wa Mukalay A, **Filetti S**, Vigneri R. Iodine induced thyrotoxicosis in Kivu, Zaire. *Lancet.* 1996 ; 347(9000):552-3.
 184. Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, **Filetti S**, Suárez HG. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. *Oncogene.* 1995;11(9):1907-11.
 185. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, Du Villard JA, Caillou B, Monier R, Rapoport B, **Filetti S**. Genetic alterations in thyroid hyperfunctioning adenomas. *J Clin Endocrinol Metab.* 1995;80(4):1347-51.
 186. Bartolone L, Regalbuto C, Benvenaga S, **Filetti S**, Trimarchi F, Pontecorvi A. Three new mutations of thyroid hormone receptor beta associated with resistance to thyroid hormone. *J Clin Endocrinol Metab.* 1994;79(1):323-6.
 187. Russo D, Damante G, Foti D, Costante G, **Filetti S**. Different molecular mechanisms are involved in the multihormonal control of glucose transport in FRTL5 rat thyroid cells. *J Endocrinol Invest.* 1994;17(5):323-7.
 188. Foti D, Damante G, Russo D, Distefano M, Grasso G, Fusco A, **Filetti S**. Molecular mechanisms of the increased glucose transport in transformed FRTL 5 rat thyroid cells. *Biochem Biophys Res Commun.* 1993; 191(1):289-94.
 189. Foti D, Russo D, Costante G, **Filetti S**. The biological activity of bovine and human thyrotropin is differently affected by trypsin treatment of human thyroid cells: thyroid stimulating antibody is related to human thyrotropin. *J Clin Endocrinol Metab.* 1991;73(4):710-6.
 190. **Filetti S**, Foti D, Costante G, Rapoport B. Recombinant human thyrotropin (TSH) receptor in a radioreceptor assay for the measurement of TSH receptor autoantibodies. *J Clin Endocrinol Metab.* 1991;72(5):1096-101.
 191. Foti D, Catalfamo R, Russo D, Costante G, **Filetti S**. Lack of relationship between 3',5'cyclic adenosine monophosphate desensitization and thyrotropin receptor down regulation in the rat thyroid cell line FRTL5. *J Endocrinol Invest.* 1991;14(3):213-8.
 192. Damante G, Russo D, Foti D, Grasso G, **Filetti S**. Effect of thyrotropin and cAMP on FRTL5 cell

- growth in a serum free medium. *J Endocrinol Invest.* 1990;13(5):397 402.
193. Belfiore A, Garofalo MR, Giuffrida D, Runello F, **Filetti S**, Fiumara A, Ippolito O, Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves' disease. *J Clin Endocrinol Metab.* 1990;70(4):830 5.
 194. Kaufman KD, **Filetti S**, Seto P, Rapoport B. Recombinant human thyroid peroxidase generated in eukaryotic cells: a source of specific antigen for the immunological assay of antimicrosomal antibodies in the sera of patients with autoimmune thyroid disease. *J Clin Endocrinol Metab.* 1990; 70(3):724 8.
 195. Belfiore A, Giuffrida D, La Rosa GL, Ippolito O, Russo G, Fiumara A, Vigneri R, **Filetti S**. High frequency of cancer in cold thyroid nodules occurring at young age. *Acta Endocrinol (Copenh).* 1989; 121(2):197 202.
 196. Damante G, Chazenbalk G, Russo D, Rapoport B, Foti D, **Filetti S**. Thyrotropin regulation of thyroid peroxidase messenger ribonucleic acid levels in cultured rat thyroid cells: evidence for the involvement of a nontranscriptional mechanism. *Endocrinology.* 1989;124(6):2889 94
 197. **Filetti S**, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH. The role of thyroid stimulating antibodies of Graves' disease in differentiated thyroid cancer. *N Engl J Med.* 1988;318(12):753 9
 198. Damante G, **Filetti S**, Rapoport B. The functional activity of the rat c Ha ras promoter requires the coordinate involvement of multiple elements. *FEBS Lett.* 1987;225(1 2):264 8.
 199. Magnusson RP, Chazenbalk GD, Gestautas J, Seto P, **Filetti S**, DeGroot LJ, Rapoport B. Molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. *Mol Endocrinol.* 1987; 1(11):856 61.
 200. Damante G, **Filetti S**, Rapoport B. Studies on the promoter region of the c Ha ras gene in FRTL5 rat thyroid cells. *Mol Endocrinol.* 1987;1(10):729 34.
 201. Damante G, Foti D, Catalfamo R, **Filetti S**. Desensitization of the thyroid cyclic AMP response to thyroid stimulating immunoglobulin: comparison with TSH. *Metabolism.* 1987;36(8):768 73.
 202. **Filetti S**, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. *Endocrinology.* 1987;120(6):2576 81.
 203. Trischitta V, Damante G, Foti D, **Filetti S**. Insulin binding and biological activities in the FRTL 5 rat thyroid cell line. *Metabolism.* 1987;36(4):379 83.
 204. Hirayu H, Seto P, Magnusson RP, **Filetti S**, Rapoport B. Molecular cloning and partial characterization of a new autoimmune thyroid disease related antigen. *J Clin Endocrinol Metab.* 1987;64(3):578 84.
 205. Damante G, **Filetti S**, Rapoport B. Nucleotide sequence and characterization of the 5' flanking region of the rat Ha ras protooncogene. *Proc Natl Acad Sci U S A.* 1987;84(3):774 8.
 206. Karpman BA, Rapoport B, **Filetti S**, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. *J Clin Endocrinol Metab.* 1987;64(1):119 23.
 207. Rapoport B, Damante G, Dere W, **Filetti S**. Studies on the promoter region of the c Ha ras oncogene. *Horm Metab Res Suppl.* 1987;17:57 62. No abstract available.
 208. **Filetti S**, Vetri M, Damante G, Belfiore A. Thyroid autoregulation: effect of iodine on glucose transport in cultured thyroid cells. *Endocrinology.* 1986;118(4):1395 400.
 209. Rapoport B, **Filetti S**, Seto P. On the mechanism of 'escape' from desensitization of the cyclic AMP response to TSH in cultured human thyroid cells. *Mol Cell Endocrinol.* 1984 Jul;36(3):181 6.
 210. **Filetti S**, Rapoport B. Autoregulation by iodine of thyroid protein synthesis: influence of iodine on amino acid transport in cultured thyroid cells. *Endocrinology.* 1984;114(4):1379 85.
 211. Rapoport B, Greenspan FS, **Filetti S**, Pepitone M. Clinical experience with a human thyroid cell bioassay for thyroid stimulating immunoglobulin. *J Clin Endocrinol Metab.* 1984;58(2):332 8.
 212. **Filetti S**, Rapoport B. Evidence that organic iodine attenuates the adenosine 3',5' monophosphate response to thyrotropin stimulation in thyroid tissue by an action at or near the adenylate cyclase catalytic unit. *Endocrinology.* 1983 Nov;113(5):1608 15.
 213. Rapoport B, **Filetti S**, Takai NA. Differential effect of protein synthesis inhibition on TSH desensitization at different stages of primary thyroid cell culture. *Endocrinology.* 1983;112(5):1874 6.
 214. Pezzino V, Distefano G, Belfiore A, **Filetti S**, Mazzone D, Grasso S. Role of thyrotrophin releasing hormone in the development of pituitary thyroid axis in four anencephalic infants. *Acta Endocrinol (Copenh).* 1982 Dec;101(4):538 41.
 215. Rapoport B, **Filetti S**, Takai N, Seto P, Halverson G. Studies on the cyclic AMP response to thyroid stimulating immunoglobulin (TSI) and thyrotropin (TSH) in human thyroid cell monolayers. *Metabolism.* 1982 Nov;31(11):1159 67.
 216. Rapoport B, **Filetti S**, Takai N, Seto P. Studies on the desensitization of the cyclic AMP response to thyrotropin in thyroid tissue. *FEBS Lett.* 1982;146(1):23 7.
 217. Takai NA, Rapoport B, **Filetti S**. High performance gel permeation chromatography of bovine thyrotropin (TSH): effect of column stability and mobile phase variation. *Horm Metab Res.* 1982; 14(8):429 32.
 218. Rapoport B, Takai NA, **Filetti S**. Evidence for species specificity in the interaction between thyrotropin and thyroid stimulating immunoglobulin and their receptor in thyroid tissue. *J Clin Endocrinol Metab.* 1982;54(5):1059 62.
 219. **Filetti S**, Rapoport B. Inhibitors of specific aminoacyl tRNA synthetases prevent thyrotropin induced desensitization in cultured human thyroid cells. *J Biol Chem.* 1982 Feb 10;257(3):1342 6.
 220. **Filetti S**, Rapoport B, Aron DC, Greenspan FC, Wilson CB, Fraser W. TSH and TSH subunit production by human thyrotrophic tumour cells in monolayer culture. *Acta Endocrinol (Copenh).* 1982;99(2):224 31.
 221. **Filetti S**, Takai N, Rapoport B. Influence of cell density on desensitization of the thyroid cell cyclic adenosine 3',5' monophosphate response to thyrotropin stimulation. *Endocrinology.* 1981;109(4):1156 63.
 222. Takai NA, **Filetti S**, Rapoport B. Studies on the bioactivity of radioiodinated highly purified bovine thyrotropin: analytical polyacrylamide gel electrophoresis. *Endocrinology.* 1981;109(4):1144 9
 223. **Filetti S**, Rapoport B. Hormonal stimulation of eucaryotic cell ADP ribosylation. *J Clin Invest.* 1981;68(2):461 7.
 224. **Filetti S**, Takai NA, Rapoport B. Insulin receptor down regulation, prevention at a post receptor site.

- Endocrinology. 1981;108(6):2409 11.
225. Hinds WE, Takai N, Rapoport B, **Filetti S**, Clark OH. Thyroid stimulating immunoglobulin bioassay using cultured human thyroid cells. J Clin Endocrinol Metab. 1981;52(6):1204 10.
 226. **Filetti S**, Takai NA, Rapoport B. Prevention by nicotinamide of desensitization to thyrotropin stimulation in cultured human thyroid cells. J Biol Chem. 1981;256(3):1072 5.
 227. Pezzino V, **Filetti S**, Belfiore A, Proto S, Donzelli G, Vigneri R. Serum thyroglobulin levels in the newborn. J Clin Endocrinol Metab. 1981;52(2):364 6.
 228. Takai NA, **Filetti S**, Rapoport B. Studies on the bioactivity of radiolabeled, highly purified bovine thyrotropin. Biochem Biophys Res Commun. 1980;97(2):566 73.
 229. Grasso S, **Filetti S**, Mazzone D, Pezzino V, Vigo R, Vigneri R. Thyroid pituitary function in eight anencephalic infants. Acta Endocrinol (Copenh). 1980;93(4):396 401.
 230. **Filetti S**, Catanuso A, Lisi E, Pezzino V, Sangiorgio L, Squatrito S, Vigneri R. Measurement of reverse triiodothyronine in dried blood spot: methodology and clinical application as a screening procedure for detection of congenital hypothyroidism. Metabolism. 1980;29(2):141 5.
 231. Calandra C, Drago F, **Filetti S**. Case of memory disorder treated with vasopressin. Minerva Psichiatr. 1980 Jan Mar;21(1):63 6. Italian.
 232. Vigneri R, **Filetti S**, Lisi E, Squatrito S, Polosa P. Reverse T3 and screening for congenital hypothyroidism. J Endocrinol Invest. 1978 ;1(4):385 7. No abstract available.
 233. Delange F, Vigneri R, Trimarchi F, **Filetti S**, Pezzino V, Squatrito S, Bourdoux P, Ermans AM. Etiological factors of endemic goiter in north eastern Sicily. J Endocrinol Invest. 1978;1(2):137 42.
 234. Pezzino V, Vigneri R, Squatrito S, **Filetti S**, Camus M, Polosa P. Increased serum thyroglobulin levels in patients with nontoxic goiter. J Clin Endocrinol Metab. 1978;46(4):653 7.
 235. Pezzino V, Cozzani P, **Filetti S**, Galbiati A, Lisi E, Squatrito S, Vigneri R. A radioimmunoassay for human thyroglobulin: methodology and clinical applications. Eur J Clin Invest. 1977;7(6):503 8.
 236. **Filetti S**, Camus M, Rodesch F, Delange F, Vigneri R, Ermans AM. Decreased reverse triiodothyronine (RT3) concentration in amniotic fluid in fetal hypothyroidism. Arch Dis Child. 1977;52(5):430 1. No abstract available.
 237. Vigneri R, Pezzino V, **Filetti S**, Squatrito S, Corso A, Maricchiolo M, Polosa P, Scapagnini U. Thyrotropin and prolactin response to intraspinal TRH administration in man. Neuroendocrinology. 1977;23(3):171 80.
 238. Vigneri R, Squatrito S, Pezzino V, **Filetti S**, Branca S, Polosa P. Growth hormone levels in diabetes. Correlation with the clinical control of the disease. Diabetes. 1976;25(3):167 72.
 239. Vigneri R, Pezzino V, **Filetti S**, Squatrito S, Galbiati A, Polosa P. Effect of dexamethasone on thyroid hormone response to TSH. Metabolism. 1975;24(11):1209 13.
 240. Vigneri R, Squatrito S, Pezzino V, **Filetti S**, Polosa P. The effect of short term triiodothyronine administration on thyroxine response to exogenous TSH in man. J Clin Endocrinol Metab. 1975;41(5):974 6.
 241. **Filetti S**, Galbiati A, Trimarchi F, Vigneri R. A radioimmunoassay for thyroxine in unextracted serum. J Nucl Biol Med. 1975;19(2):86 93.
 242. Vigneri R, **Filetti S**, Galbiati A, Pezzino V, Squatrito S, Polosa P. Effect of dexamethasone on triiodothyronine (T3) response to TSH. J Nucl Biol Med. 1975;19(1):29 31.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196/2003, che il presente curriculum verrà allegato al programma dell'evento formativo e pubblicato nella banca dati presente nel sito <http://ecm.agenas.it>, e a tal fine presto il consenso al trattamento dei dati personali ivi contenuti.

Data, 30/07/2015

Firma

